Avisi Technologies

Somewhere in the United States, a glaucoma patient is walking around with a piece of nanotechnology drainage hardware tucked into their eye, doing its quiet job of letting fluid out before pressure builds up. The patient barely knows it's there. That is exactly the design brief. In early 2026, Avisi Technologies announced its first patient had been implanted with VisiPlate in the SAPPHIRE pivotal trial - the moment a decade-long lab idea stopped being a slide and became a thing that lives in people.

Avisi is a clinical-stage ophthalmic medical device company headquartered in Redwood City, California. It has roughly nineteen employees, a flagship device thinner than most things you can name, and a single, unglamorous obsession: the pressure inside the human eye. The company just closed a $10.7M Series A. It has raised about $21.7M in total. And it is built around a bet that the leading cause of irreversible blindness is, at heart, a plumbing problem.

Glaucoma is a pressure disease. Fluid called aqueous humor is constantly produced inside the eye and is supposed to drain out at the same rate. When the drainage clogs, pressure climbs, the optic nerve takes the damage, and vision goes - permanently. More than 133 million people worldwide have it. Roughly half don't know. There is no cure, only management.

Surgeons have tried to solve this for decades by installing drainage shunts. The trouble is the body. Implant something foreign in the eye and the body answers with scar tissue, which is wonderful for healing cuts and terrible for keeping a tiny drain open. Scarring is the reason a lot of glaucoma surgery fails over time. So the real problem was never "can we drain the eye." It was "can we drain the eye for years without the body sealing the drain shut."

In 2017, Rui Jing Jiang and Brandon Kao were University of Pennsylvania students staring at a challenge from Penn's Y-Prize competition. The raw ingredient was a metamaterial out of Professor Igor Bargatin's engineering lab - an absurdly thin, ultralight structure originally imagined for things like floating, aerospace-grade membranes. Most people looked at it and thought "flight." Jiang and Kao looked at it and thought "eye."

The bet was this: if you could make a drainage device thin enough and from the right biocompatible materials - alumina and a polymer coating called Parylene-C - the body might not mount the same scarring attack it reserves for bulkier implants. Thin enough to be ignored. That was the whole wager. They won the President's Innovation Prize, took grant money from the National Science Foundation, went through MedTech Innovator and J&J's JLABS, and turned a class project into a company.

It is a faintly ironic origin story: a technology designed to be weightless and escape the ground, repurposed to settle permanently into one of the most delicate, unforgiving environments in the body. The eye does not tolerate guests. Avisi's entire pitch is that VisiPlate is a guest the eye won't notice.

VisiPlate is an ultrathin aqueous shunt - roughly twenty times thinner than a human hair. Instead of one drainage path, it uses a network of multiple, redundant microchannels. If you only build one drain and it clogs, you've failed. Build many, and the device keeps working even as the eye does its worst. It's made from biocompatible alumina and Parylene-C, chosen specifically to keep the foreign-body response - the scarring - to a minimum.

That is the elegance: the same thinness that makes it nearly invisible is also what makes it gentle. Less bulk, less irritation, less scar. And Avisi isn't stopping at one device.

A clinical-stage device company doesn't have revenue to point to. It has milestones, capital, and conviction. Here's the funding climb that carried Avisi from a campus prize to a pivotal trial.

The Series A came together in February 2026, led by MedVenture Partners, with a roster of new backers - Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, OneOneFive - and returning investors including Good Growth Capital and Quaker Capital Investments. The money is aimed squarely at the SAPPHIRE pivotal trial and the broader glaucoma pipeline. Along the way Avisi has collected the Glaucoma Foundation's H. Dunbar Hoskins International Innovation Award and an Octane Ophthalmology Technology Summit People's Choice Award, and CEO Rui Jing Jiang was named one of Greater Philadelphia's Inno Under 25.

Avisi's stated mission is plain: restore health and promote vitality through accessible, cutting-edge healthcare. The vision behind it is bigger - a world where good eye care isn't rationed, beginning with the world's leading cause of irreversible blindness. Picking glaucoma first is a deliberate choice. It's common, it's underdiagnosed, and the existing fixes fail too often. If you can crack that, you've earned the right to talk about the rest.

The culture reflects where it came from: interdisciplinary, built at the seam between materials engineering and ophthalmology, run by a young founding team with an experienced clinical and regulatory board sitting behind them. It's a company that treats a scarring problem as a materials problem - which is a quietly radical reframing.

Return to the patient from the opening - the one walking around with a sliver of nanotechnology quietly draining their eye. A few years ago that sentence was a hypothesis on a grant application. Now it's a person in a clinical trial. The SAPPHIRE trial is the test that decides whether the founders' bet about thinness and scarring holds up at scale, in real eyes, over real time.

If it works, the implications stretch past one device. Aging populations mean more glaucoma; by 2040 the global count is projected to keep climbing. A drainage device that the body genuinely tolerates - paired with a drug-delivery platform behind it - is the difference between managing decline and actually holding the line. Avisi hasn't won yet. It has a trial, a pipeline, and $21.7M of other people's conviction. But the speck is already inside the eye, doing its quiet job. The rest is data.